Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., Tykodi, S. S., Grimm, M., Gurney, H., Leibowitz-Amit, R., Geertsen, P. F., Amin, A., Tomita, Y., McHenry, M. B., Saggi, S. S., & Tannir, N. M. (2020). survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Journal for immunotherapy of cancer, 8(2), . http://access.bl.uk/ark:/81055/vdc_100127564613.0x00002b